Chemistry:Janagliflozin
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H29ClO6 |
| Molar mass | 460.95 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Janagliflozin is an experimental SGLT2 inhibitor developed by Sihuan Pharmaceutical.[1][2][3][4][5][6]
References
- ↑ Song, Ling; Yao, Xueting; Liu, Yang; Zhong, Wen; Jiang, Ji; Liu, Hongzhong; Zhou, Huimin; Shi, Chongtie et al. (April 2020). "Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods". European Journal of Pharmaceutical Sciences 147: 105281. doi:10.1016/j.ejps.2020.105281.
- ↑ Liu, Dongyang; Song, Ling; Wang, Xiaoxu; Liu, Xu; Cao, Fangrui; Liu, Hongzhong; Ding, Yanhua; Xiao, Xinhua et al. (1 June 2019). "154-LB: Accelerating Clinical Development of Janagliflozin, a Novel Antidiabetic Drug, Using Model-Informed Drug Development Strategy". Diabetes 68 (Supplement_1). doi:10.2337/db19-154-LB.
- ↑ Zhao, Hengli; Wei, Yilin; He, Kun; Zhao, Xiaoyu; Mu, Hongli; Wen, Qing (December 2022). "Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model". European Journal of Pharmaceutical Sciences 179: 106298. doi:10.1016/j.ejps.2022.106298. PMID 36162752.
- ↑ Zhao, Hengli; Zhao, Zhirui; He, Kun; Mi, Nianrong; Lou, Kai; Dong, Xiaolin; Zhang, Wenyu; Sun, Jingfang et al. (August 2023). "Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment". Clinical Pharmacokinetics 62 (8): 1093–1103. doi:10.1007/s40262-023-01256-0. PMID 37284974.
- ↑ Gao, Leili; Cheng, Zhifeng; Su, Benli; Su, Xiuhai; Song, Weihong; Guo, Yushan; Liao, Lin; Chen, Xiaowen et al. (March 2023). "Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial". Diabetes, Obesity and Metabolism 25 (3): 785–795. doi:10.1111/dom.14926. PMID 36433709.
- ↑ Ji, Linong; Jiang, Xiaozhen; Hao, Qingshun; Cheng, Zhifeng; Wang, Kun; Pang, Shuguang; Liu, Meiying; Guo, Yushan et al. (May 2023). "Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial". Diabetes, Obesity and Metabolism 25 (5): 1229–1240. doi:10.1111/dom.14971. PMID 36594724.
 |  |
